HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor treatments. With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expanded Access Program (EAP), commonly known as "compassionate use." NEW YORK, March 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies, today announced its intention to submit an Expanded Access application for HT-001, its novel therapeutic candidate for t

The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place March 7-11, 2025, highlighting HT-001 as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities. The recent case study will be highlighted that demonstrated the efficacy of HT-001 2% cream in a 59-year-old patient with metastatic breast cancer undergoing treatment with paclitaxel, trastuzumab, and pertuzumab. The patient developed pruritic, burning red papules on the face, scalp, and upper back, a known dermatologic side effect of EGFR inhibitors. After just one week of applying HT-001 2% cream twice daily, the patient experienced full symptom and lesion

Research Demonstrates GDNF's Ability to Prevent and Reverse Obesity by Enhancing Fat Metabolism and Energy ExpenditureHoth is developing this therapeutic in Partnership with the Department of Veterans AffairsKey Findings from the Study: Protection Against High-Fat Diet-Induced Obesity – GDNF-tg mice exhibited significantly lower body weight and reduced fat deposition despite consuming a high-fat diet.Enhanced Fat Burning and Energy Expenditure – GDNF increased basal metabolic rate, oxygen consumption, and carbon dioxide production, leading to higher energy expenditure without changes in food intake.Inhibition of Fat Cell Formation (Adipogenesis) – GDNF suppressed key genes involved in fat st

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

424B5 - Hoth Therapeutics, Inc. (0001711786) (Filer)

8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir

SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)

SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)